Published in AAPS PharmSciTech on February 11, 2015
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med (1999) 9.84
Amphotericin B: 30 years of clinical experience. Rev Infect Dis (1990) 5.82
Structure and design of polymeric surfactant-based drug delivery systems. J Control Release (2001) 3.48
Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release (2005) 2.79
Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release (2004) 2.43
Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm (2004) 1.98
Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect (2001) 1.91
Amphotericin B nephrotoxicity. J Antimicrob Chemother (2002) 1.64
Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother (1992) 1.60
Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev (2002) 1.50
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs (2013) 1.44
Progress of drug-loaded polymeric micelles into clinical studies. J Control Release (2014) 1.42
Novel pH sensitive block copolymer micelles for solvent free drug loading. Macromol Biosci (2006) 1.08
Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules (2003) 0.96
Encapsulation of hydrophobic drugs in polymeric micelles through co-solvent evaporation: the effect of solvent composition on micellar properties and drug loading. Int J Pharm (2006) 0.92
Block copolymer micelles for the encapsulation and delivery of amphotericin B. Pharm Res (2002) 0.90
In vitro dissociation of antifungal efficacy and toxicity for amphotericin B-loaded poly(ethylene oxide)-block-poly(beta benzyl L aspartate) micelles. J Control Release (1998) 0.89
Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J Control Release (2003) 0.86
Optimization of bioassay method for the quantitative microbiological determination of amphotericin B. Mycoses (2009) 0.86
Fluorescence of amphotericin B-deoxycholate (fungizone) monomers and aggregates and the effect of heat-treatment. Langmuir (2007) 0.84
Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. Biomaterials (2013) 0.84
Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation. Eur J Pharm Sci (2010) 0.83
Development of polyion complex micelles for encapsulating and delivering amphotericin B. Biomaterials (2009) 0.83
Aggregation and Polymerization of PEG-Based Macromonomers with Methacryloyl Group as the Only Hydrophobic Segment. J Colloid Interface Sci (2001) 0.82
Preparation, development and in vitro release evaluation of amphotericin B-loaded amphiphilic block copolymer vectors. Int J Pharm (2014) 0.78
New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp. Int J Pharm (2014) 0.78
Evaluation of the Neo-Sensitabs diffusion method for determining the antifungal susceptibilities of Cryptococcus gattii isolates, using three different agar media. Rev Iberoam Micol (2008) 0.77
Controlled block copolymer micelle formation for encapsulation of hydrophobic ingredients. Eur Phys J E Soft Matter (2013) 0.77
Chemical modification of hydrophobic block in poly(ethylene oxide) poly(caprolactone) based nanocarriers: effect on the solubilization and hemolytic activity of amphotericin B. Macromol Biosci (2010) 0.77
Amphotericin B aggregation inhibition with novel nanoparticles prepared with poly(epsilon-caprolactone)/poly(n,n-dimethylamino-2-ethyl methacrylate) diblock copolymer. J Microbiol Biotechnol (2011) 0.76